Newsfile Corp
02 Jun 2026, 03:13 UTC · 2h ago
ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
Search tags
Newsfile Corp
02 Jun 2026, 03:13 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
Immutep Ltd. is facing a securities class action lawsuit alleging it misled investors regarding the status and prospects of the TACTI-004 trial. — Lawsuits alleging clinical trial deception typically trigger investor distrust and can signal upcoming negative trial results.
-0.60The lawsuit claims Immutep was aware of internal data suggesting the TACTI-004 study faced a material risk of failing its primary efficacy and safety endpoints. — Specific allegations of trial failure risk directly threaten the company's primary asset pipeline and future valuation.
-0.50The class period for affected ADR purchasers is defined as March 24, 2025, through March 12, 2026. — Defines the scope of potential financial liability for the company, though less impactful than the underlying trial risk.
-0.10Ticker attribution
Continue reading
6 related stories
Model heads
The company is mentioned as the subject of a securities class action lawsuit notice.
The company is mentioned as the subject of a securities class action lawsuit notice.
The company is facing a securities class action lawsuit alleging false and misleading statements regarding clinical trial prospects.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Newsfile Corp
2h ago
